Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Anlotinib, and Taxane-Based Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07581821Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in nasopharyngeal carcinoma (NPC). Primary endpoint: Objective Response Rate at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07581821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581821.